CRISPR THERAPEUTICSCS AG
Acción · CH0334081137 · CRSP · A2AT0Z (XNMS)
41,35 USD
13.06.2025 23:45
Cotizaciones actuales de CRISPR THERAPEUTICSCS AG
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() NASDAQ |
CRSP
|
USD
|
13.06.2025 23:45
|
41,35 USD
| 41,28 USD
+0,17 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,00 % | -1,31 % | 16,15 % | -1,83 % | -5,55 % | -34,94 % | -30,96 % |
Perfil de la empresa para CRISPR THERAPEUTICSCS AG Acción
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Fondos invertidos
Los siguientes fondos han invertido en: CRISPR THERAPEUTICSCS AG invertido:
Fondo | Vol. en millones 318,68 | Porcentaje (%) 0,75 % |
Datos de la empresa
Nombre CRISPR THERAPEUTICSCS AG
Empresa CRISPR Therapeutics AG
Símbolo CRSP
Sitio web
https://www.crisprtx.com
Mercado principal
NASDAQ/NMS (GLOBAL MARKET)
WKN A2AT0Z
ISIN CH0334081137
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Samarth Kulkarni Ph.D.
Capitalización de mercado 3 Mrd.
País Suiza
Moneda USD
Empleados 0,4 T
Dirección Baarerstrasse 14, 6300 Zug
Fecha de OPV 2016-10-19
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | 1CG.F |
NASDAQ | CRSP |
Otras acciones
Los inversores que tienen CRISPR THERAPEUTICSCS AG también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.